These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 10168180)

  • 1. The impact of methodological and drug development issues on the use of economic data generated by clinical trials.
    Miller DW
    Pharm Pract Manag Q; 1997 Jul; 17(2):75-86. PubMed ID: 10168180
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic evaluation.
    Drummond MF; Aguiar-Ibanez R; Nixon J
    Singapore Med J; 2006 Jun; 47(6):456-61; quiz 462. PubMed ID: 16752012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluations and diabetes.
    Pathak DS; Burke TA
    Pharm Pract Manag Q; 1998 Jan; 17(4):17-24. PubMed ID: 10174745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological issues in the economic analysis of cancer treatments.
    Tappenden P; Chilcott J; Ward S; Eggington S; Hind D; Hummel S
    Eur J Cancer; 2006 Nov; 42(17):2867-75. PubMed ID: 17023160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies and pitfalls in quality of life research.
    Brown RS
    Hepatology; 1999 Jun; 29(6 Suppl):9S-12S. PubMed ID: 10386076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring quality of life.
    Epstein RS
    Healthplan; 1997; 38(6):17-8, 22-4. PubMed ID: 10176882
    [No Abstract]   [Full Text] [Related]  

  • 9. Funding patient-reported outcomes in cancer clinical trials.
    Moinpour CM; Denicoff AM; Bruner DW; Kornblith AB; Land SR; O'Mara A; Trimble E
    J Clin Oncol; 2007 Nov; 25(32):5100-5. PubMed ID: 17991928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market.
    Hay JW; Yu WM
    Value Health; 2000; 3(3):181-5. PubMed ID: 16464182
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
    Evans WK; Coyle D; Gafni A; Walker H;
    Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring costs: administrative claims data, clinical trials, and beyond.
    Etzioni R; Riley GF; Ramsey SD; Brown M
    Med Care; 2002 Jun; 40(6 Suppl):III63-72. PubMed ID: 12064760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of three physiotherapy treatments for non-specific neck disorders alongside a randomized trial.
    Lewis M; James M; Stokes E; Hill J; Sim J; Hay E; Dziedzic K
    Rheumatology (Oxford); 2007 Nov; 46(11):1701-8. PubMed ID: 17956916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
    Kessler LA; Waterer GW; Barca R; Wunderink RG
    Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations.
    Reinharz D; Saldaña VR; Follador W; Asche C
    Int J Technol Assess Health Care; 2001; 17(4):571-8. PubMed ID: 11758300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpretation of quality-of-life outcomes: issues that affect magnitude and meaning.
    Testa MA
    Med Care; 2000 Sep; 38(9 Suppl):II166-74. PubMed ID: 10982103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of two physiotherapy interventions for primary care back and neck pain patients: cost effectiveness analysis.
    Manca A; Dumville JC; Torgerson DJ; Klaber Moffett JA; Mooney MP; Jackson DA; Eaton S
    Rheumatology (Oxford); 2007 Sep; 46(9):1495-501. PubMed ID: 17711873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care costing: data, methods, current applications.
    Lipscomb J; Yabroff KR; Brown ML; Lawrence W; Barnett PG
    Med Care; 2009 Jul; 47(7 Suppl 1):S1-6. PubMed ID: 19536004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.